Skip to content
Ofev
Active ingredient: Nintedanib

Ofev

Quality products
24/7 Support
Fast delivery
Delivery from 4 days
Select pack Package Per unit Price

Free delivery on orders from $ 312.00, free express delivery from $ 468.00

Secure Payments
Track your order
Best price guarantee

Ofev capsules are used for adults with idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung disease, or systemic sclerosis-associated interstitial lung disease. The treatment helps slow disease progression by acting on cellular pathways involved in abnormal lung scarring.

Overview

Ofev contains nintedanib, an anti-fibrotic medicine classified as a multi-kinase inhibitor. The active pharmaceutical substance is supplied as nintedanib, formulated in the capsule as nintedanib esilate.

Dosage and administration

The dose is decided individually, taking age, other medicines, and health conditions into account. In routine adult treatment, the prescribed regimen is taken orally at regular intervals, with the exact strength and frequency selected by the treating clinician.

Key administration points include:

  • Take each capsule with food.
  • Swallow the capsule whole with liquid.
  • Keep doses spaced as evenly as possible when more than one daily dose is prescribed.
  • Do not chew, crush, open, or dissolve the capsule.
  • If a dose is missed, do not double the next dose.
  • If vomiting occurs soon after administration, obtain individualized instructions before taking an extra capsule.

Food is not a minor detail with Ofev. Taking the capsule with a proper meal can improve gastrointestinal tolerability. A small snack may be inadequate for some patients who develop nausea or diarrhoea, so meal timing should be discussed with the treatment team.

Choose two regular meal times that fit the prescribed schedule and use the same routine each day. A phone reminder can help when fatigue or breathlessness makes daily planning difficult.

Treatment duration depends on disease behaviour, lung-function results, adverse effects, and the clinician’s assessment. Ofev is generally used as long-term disease-modifying therapy when the expected benefit continues to outweigh the risks.

Formulation

Ofev contains nintedanib, formulated in the capsules as nintedanib esilate. The dose is determined individually, taking the person's age, other medicines, and health conditions into account.

How it affects the body

Nintedanib acts on several receptor tyrosine kinases involved in the signalling processes that promote fibroblast activity, abnormal connective-tissue formation, and vascular changes. By reducing these signals, it can slow the biological processes associated with progressive pulmonary fibrosis.

The term multi-kinase inhibitor describes a medicine that blocks more than one kinase pathway. Kinases are enzymes that transmit growth and activation signals inside cells. In pulmonary fibrosis, several of these pathways can contribute to the persistence and expansion of scar-forming activity.

Therapeutic indications

Ofev is an oral anti-fibrotic treatment for selected progressive fibrosing lung diseases. It is prescribed in adults with idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases that show a progressive phenotype, and systemic sclerosis-associated interstitial lung disease. The aim is to slow the decline in lung function rather than reverse established scar tissue.

Idiopathic pulmonary fibrosis, or IPF, causes gradual thickening and scarring of lung tissue without an identified cause. Chronic fibrosing interstitial lung diseases can arise from several underlying disorders and may continue to worsen despite treatment of the original condition. Systemic sclerosis-associated interstitial lung disease occurs when systemic sclerosis affects the lungs and produces inflammation or fibrosis.

Ofev treatment is usually managed by a respiratory physician or an interstitial lung disease clinic. Lung-function testing, symptom assessment, liver tests, and review of other medicines help determine whether treatment remains suitable.

Clinical trial evidence and regulatory assessments support the use of Ofev for slowing functional decline in these conditions [1].

Targeted Pulmonary Conditions

The principal clinical settings include:

  • Idiopathic pulmonary fibrosis: a chronic disease marked by progressive lung scarring and reduced gas exchange.
  • Chronic fibrosing interstitial lung disease with a progressive phenotype: disease that continues to worsen through declining lung function, increasing symptoms, or radiological progression.
  • Systemic sclerosis-associated interstitial lung disease: pulmonary involvement linked to systemic sclerosis.

Ofev does not restore normal lung tissue that has already become fibrotic. Its role is disease modification: slowing progression may help preserve breathing capacity for longer.

A useful practical distinction is that treatment response is often assessed through lung-function trends rather than an immediate change in breathlessness. A patient may feel similar while testing shows a slower decline.

Common mistakes

Several avoidable habits can make Ofev harder to tolerate:

  • Taking capsules on an empty stomach despite repeated nausea or diarrhoea.
  • Chewing, opening, or crushing the soft gelatin capsule.
  • Taking an extra capsule after a missed dose.
  • Stopping treatment abruptly without a replacement plan or clinical review.
  • Ignoring repeated loose stools and becoming dehydrated.
  • Missing liver-function appointments.
  • Failing to mention an upcoming operation.
  • Treating herbal products as automatically free from interactions.
  • Continuing treatment despite jaundice, black stools, or severe abdominal pain.
  • Assuming that stable symptoms mean the disease has stopped progressing.

One small operational detail matters: keep a record of bowel symptoms for several days rather than describing them only as “bad.” Frequency, urgency, nighttime episodes, and fluid intake give the clinician more useful information.

Another common mistake is changing the dose because a capsule feels difficult to tolerate. Dose reductions can be part of medical management, but they should be prescribed rather than improvised.

Reasons not to use it

Ofev should not be used in a person with a serious hypersensitivity to nintedanib or a relevant capsule component. Pregnancy requires specific attention because nintedanib may cause fetal harm. People who could become pregnant may need pregnancy testing and reliable contraception during treatment, based on clinical advice.

  • Moderate or severe hepatic impairment, Child-Pugh B or C.
  • Serious hypersensitivity to nintedanib or a relevant capsule component.
  • Pregnancy, because nintedanib may cause fetal harm.

Moderate-to-severe hepatic impairment corresponds to Child-Pugh B or C and is a clear treatment boundary in European Medicines Agency product information. The EMA EPAR also describes dose management and safety monitoring for Ofev [3].

When this is not for you

Ofev may not be for you if moderate-to-severe liver impairment, a serious nintedanib allergy, or another major treatment risk is present. A treatment plan requires special review when liver function is impaired, bleeding risk is high, pregnancy is possible, or major surgery is planned.

Tell the prescriber about:

  • Chronic liver disease or previous hepatitis.
  • A history of significant bleeding.
  • Anticoagulant or antiplatelet treatment.
  • Recent abdominal surgery or gastrointestinal disease.
  • A planned operation or invasive procedure.
  • Pregnancy, breastfeeding, or plans to conceive.
  • A known allergy to nintedanib or capsule ingredients.
  • Severe cardiovascular disease or previous arterial thrombosis.
Do not wait for the next routine appointment if yellow skin, black stools, vomiting blood, severe abdominal pain, or sudden weakness develops. These symptoms need prompt assessment.

Possible side effects

Diarrhoea is one of the most frequent adverse effects associated with Ofev. Nausea, vomiting, reduced appetite, abdominal discomfort, weight loss, and tiredness can also occur. Some patients experience headache or an increase in liver enzyme results during treatment.

Practical measures may include:

  • Taking the capsule with food.
  • Replacing fluid and electrolytes after repeated loose stools.
  • Reporting persistent diarrhoea rather than waiting for dehydration.
  • Recording the number of bowel movements when symptoms begin.
  • Seeking advice if appetite falls or body weight decreases noticeably.

Liver safety requires structured monitoring. Alanine aminotransferase, aspartate aminotransferase, bilirubin, and other liver-related results may be assessed before treatment and during therapy. The monitoring schedule can be more frequent during the early months or after a dose change.

Symptoms that may indicate liver injury include yellowing of the skin or eyes, dark urine, pale stools, unusual itching, marked tiredness, or pain beneath the right ribs. These symptoms require prompt medical assessment.

Bleeding risk can increase when Ofev is used with anticoagulants or other medicines that affect haemostasis. Arterial thromboembolic events, gastrointestinal perforation, and serious liver injury are uncommon but clinically significant risks described in product information.

Ofev can also affect wound healing. Planned surgery, recent surgery, or a wound that is healing poorly should be discussed before treatment continues.

One detail patients sometimes miss is dehydration. Diarrhoea combined with reduced fluid intake can cause weakness, dizziness, and kidney stress, even when the original gastrointestinal symptom seems mild.

The FDA prescribing information describes liver-test monitoring and dose-management precautions for nintedanib [2].

Comparison

Ofev and pirfenidone are pharmacologically different anti-fibrotic approaches used in idiopathic pulmonary fibrosis. They should not be treated as interchangeable products because their mechanisms, adverse-effect patterns, monitoring needs, and administration schedules differ.

Treatment approach Main pharmacological feature Clinical monitoring focus
Ofev Multi-kinase inhibition affecting pro-fibrotic signalling Diarrhoea, liver function, bleeding and wound-healing risks
Pirfenidone Anti-fibrotic and anti-inflammatory activity through several cellular pathways Gastrointestinal effects, liver function, skin reactions and sun sensitivity

The choice depends on the diagnosed lung disease, previous treatment, liver function, comorbidities, interaction risk, and patient priorities. A physician may also consider whether the disease has a progressive fibrosing phenotype beyond IPF.

Ofev has a practical advantage for some patients because its clinical monitoring profile differs from that of pirfenidone. Its limitation is the frequency of gastrointestinal adverse effects, especially diarrhoea, and the need for careful liver monitoring.

The two therapies should not be combined independently. A switch from one anti-fibrotic treatment to another requires a planned regimen.

What doctors say

In clinical practice, respiratory specialists usually set expectations early: Ofev is intended to slow lung-function decline, not to remove established fibrosis or provide immediate relief from breathlessness.

Treatment assessment often combines forced vital capacity, oxygen needs, exercise tolerance, imaging, symptoms, and exacerbation history. A single test result rarely determines success. Trends over time are more informative. Clinicians also review weight, hydration, and gastrointestinal symptoms during follow-up. These findings help balance treatment benefit against tolerability.

Physicians also tend to manage adverse effects actively rather than waiting for a patient to stop treatment. Persistent diarrhoea may prompt hydration advice, an anti-diarrhoeal strategy, temporary interruption, or dose reduction. Liver-test changes may require a pause or further investigation.

A practical point from respiratory care is that weight loss can be easy to miss when appetite changes gradually. Weighing at consistent times can reveal a pattern before it becomes clinically serious.

Patients should bring a complete medicine list to every review. Anticoagulants, medicines affecting liver enzymes, and frequent use of non-prescription products can change the risk assessment.

Common questions

What happens when Ofev is stopped, and does it need tapering?

Stopping Ofev removes its ongoing anti-fibrotic effect, so the underlying lung disease may continue to progress according to its natural course. The 2024 Health Canada product monograph does not describe a routine tapering requirement comparable to corticosteroid withdrawal. A clinician may still plan a gradual treatment change when adverse effects, pregnancy, surgery, or another therapy is involved. Do not restart or replace Ofev independently after an interruption.

Do diet, exercise, or daily habits affect the result?

Food can improve tolerability, while dehydration can worsen the consequences of diarrhoea. Pulmonary rehabilitation, individually prescribed physical activity, smoking avoidance, vaccination planning, and adequate nutrition may support general lung care. The 2020 World Health Organization pharmacovigilance manual supports reporting suspected adverse effects, but lifestyle measures do not replace anti-fibrotic treatment. Exercise intensity should match oxygen levels, cardiovascular status, and respiratory advice.

Which specific condition rules Ofev out?

Moderate or severe hepatic impairment, classified as Child-Pugh B or C, is a major treatment boundary. The European Medicines Agency product information from 2023 states that nintedanib use is not recommended in these categories because exposure and liver-related toxicity may increase. A previous severe allergic reaction to nintedanib is another clear reason to avoid treatment. Mild liver impairment requires individualized dose management rather than automatic exclusion.

Should Ofev be taken with food or on an empty stomach?

Ofev capsules should be taken with food and swallowed whole with liquid. The 2024 Health Canada product monograph describes administration with food, which can help reduce gastrointestinal intolerance. Taking a capsule after a substantial meal may be easier than taking it with only coffee or a small snack. If diarrhoea or nausea persists despite food, the prescribed regimen may need clinical adjustment.

Does Ofev cause diarrhoea?

Yes, diarrhoea is a well-recognized adverse effect of Ofev and can become clinically significant if it causes dehydration or weight loss. The 2022 EMA Ofev product information describes diarrhoea among the most frequent treatment-related reactions. Early fluid replacement, symptom recording, and prompt contact with the treatment team can prevent complications. Severe, persistent, bloody, or nighttime diarrhoea requires medical assessment.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Customer Feedback on Ofev

3.7
Based on 3 reviews
Kevin G., 37 Quebec City Three months
Verified
Rating: 4 out of 5

The first weeks were difficult because diarrhoea interrupted work. Taking the capsules with a full breakfast and supper helped. My breathing did not suddenly improve, but my specialist said the lung tests were more stable than expected.

Oct 15, 2026
Christopher, 58 Montreal Five months
Verified
Rating: 3.5 out of 5

I had nausea and very little appetite during the first month. The dose was adjusted and I kept a simple food and symptom diary. I still had occasional loose stools, but the routine became manageable.

Oct 26, 2026
Gareth G., 53 Winnipeg Four months
Verified
Rating: 3.5 out of 5

The capsules were easy to swallow, although I disliked having regular blood tests. I missed one evening dose and did not double the next one. The main benefit for me was having a clear monitoring plan, not a dramatic change in symptoms.

Nov 13, 2026

Sources

  1. Health Canada (2024). Product Monograph — Ofev (nintedanib)
  2. U.S. Food and Drug Administration (2023). Ofev (nintedanib) Prescribing Information
  3. European Medicines Agency (2023). Ofev: EPAR — Product Information
Get our free app Shop faster and track your orders 3.8 · 504 reviews Install